Supplement

List of Investigators

Investigator	Institution	Location
Adam Brosz	Meridian Clinical Research	Grand Island, Nebraska
Laurence Chu	Benchmark Research	Austin, Texas
Michael Cotugno	Benchmark Research	Metairie, Louisiana
Brandon Essink	Meridian Clinical Research	Omaha, Nebraska
Carlos Fierro	Johnson County Clin-Trials	Lenexa, Kansas
Carl Griffin	Lynn Health Science Institute	Oklahoma City, Oklahoma
Greg Hachigian	Benchmark Research	Sacramento, California
Charles Harper. Keith Vrbicky,	Meridian Clinical Research	Norfolk, Nebraska
Jordan Whatley	Meridian Clinical Research	Baton Rouge, Louisiana

Supplementary methods Part J Study Eligibility Criteria

Inclusion Criteria

Each participant must meet all of the following criteria to be enrolled in this study:

- 1. Male or female, at least 18 years of age at the time of consent (Screening Visit).
- 2. Investigator's assessment that participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures.
- 3. Participant has provided written informed consent for participation in this study, including all evaluations and procedures as specified in this protocol.
- 4. Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥12 consecutive months prior to screening [Day 0] without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the investigator to confirm postmenopausal status.
- 5. Female participants of childbearing potential may be enrolled in the study if the participant fulfills all of the following criteria:
 - Has a negative pregnancy test on the day of vaccination (Day 1).
 - Has practiced adequate contraception (Section 10.3) or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1.
 - Has agreed to continue adequate contraception through 3 months following vaccination.
 - Is not currently breastfeeding.

Adequate female contraception is defined as consistent and correct use of a United States FDA-approved contraceptive method in accordance with the product label (Section 10.3).

6. Participant must have been either previously enrolled in the mRNA-1273-P301 (COVE) study, must have received 2 doses of mRNA-1273 in that study, with his/her second dose at least 6 months prior to enrollment in mRNA-1273-P205, and must be currently enrolled and compliant in that study (ie, has not withdrawn or discontinued early); or participant must have received 2 doses of mRNA-1273 under the EUA with their second dose at least 6 months prior to enrollment in mRNA-1273 under the EUA with their second dose at least 6 months prior to enrollment in mRNA-1273-P205; or have received a 2 dose primary series of mRNA-1273 followed by a 50 μg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under EUA at least 3 months prior to enrollment in mRNA-1273-P205; and able to provide proof of vaccination status at the time of

screening (Day 1); or for enrollment in Part A.2, participant must be currently enrolled and compliant in Part A.1 of the mRNA-1273-P205 study and must have received their first booster dose of mRNA-1273.211 50 µg; or for enrollment in Part J, participant must meet at least one of the following criteria:

- Completed enrollment in Part H of the mRNA-1273-P205 study; or
- Received a 2-dose primary series of mRNA-1273 (100 µg) followed by a 50 µg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under

EUA, followed by a 50 µg booster dose of mRNA-1273.222 under EUA at least 3 months prior to enrollment in Part J of mRNA-1273-P205; or

• Previously received a 2-dose primary series of mRNA vaccine against SARS-CoV-2 followed by a booster dose of a monovalent mRNA vaccine, followed by a second booster dose of a bivalent mRNA vaccine

Participants in Part J must also provide proof of vaccination status at the time of screening (Day 0 or Day 1).

Exclusion Criteria

Participants meeting any of the following criteria at the Screening Visit, unless noted otherwise, were excluded from the study:

- 1. Had significant exposure to someone with SARS-CoV-2 infection or coronavirus disease 2019 (Covid-19) in the past 14 days, as defined by the CDC as a close contact of someone who has had Covid-19.
- 2. Has known history of SARS-CoV-2 infection within 3 months prior to enrollment.
- 3. Is acutely ill or febrile (temperature ≥ 38.0°C/[100.4°F]) less than 72 hours prior to or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled and will retain their initially assigned participant number.
- 4. Currently has symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization for worsening disease, at the discretion of the investigator.
- 5. Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
- 6. Has a current or previous diagnosis of immunocompromising condition to include human immunodeficiency virus, immune-mediated disease requiring immunosuppressive treatment, or other immunosuppressive condition.
- 7. Has received systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to screening (for corticosteroids ≥ 10 mg/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- 8. Has known or suspected allergy or history of anaphylaxis, urticaria, or other significant AR to the vaccine or its excipients.
- 9. Has a documented history of myocarditis or pericarditis within 2 months prior to Screening Visit (Day 0).
- 10. Coagulopathy or bleeding disorder considered a contraindication to intramuscular (IM) injection or phlebotomy.
- 11. Has received or plans to receive any licensed vaccine ≤ 28 days prior to the injection (Day 1) or a licensed vaccine within 28 days before or after the study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine.
- 12. Has received systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.
- 13. Has donated \geq 450 mL of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.

- 14. Plans to participate in an interventional clinical trial of an investigational vaccine or drug while participating in this study.
- 15. Is an immediate family member or household member of study personnel, study site staff, or Sponsor personnel.
- 16. Is currently experiencing an SAE in Study mRNA-1273-P301 (COVE) at the time of screening for this study.

Immunogenicity Assays

Lentivirus-Based SARS-CoV-2 Spike-Pseudotyped Virus Neutralization Assay


SARS-CoV-2 neutralizing antibodies (nAb) in samples were assessed using a SARS-CoV-2 Spike (S)-Pseudotyped Virus Neutralization Assay (PsVNA) in 293/ACE2 cells.¹ The PsVNA quantifies nAb using lentivirus particles that express full-length spike proteins on their surface, and contain a firefly luciferase reporter gene for quantitative measurements of infection in transduced 293T cells expressing high levels of ACE2 (293T/ACE2 cells) by relative luminescence units (RLU). Serial dilution of antibodies was used to produce a dose-response curve. Neutralization was measured as the serum dilution at which RLU was reduced by 50% (ID50) relative to mean RLU in virus control wells (cells + virus but no sample) after subtraction of mean RLU in cell control wells (cells only). Positive controls were included on each assay plate in order to follow stability over time. The assay is validated for the prototypic D614G variant and the omicron BA.5/BA.5 sublineage but has not been validated for the omicron BQ.1.1 and XBB.1 sublineages.

The spike-pseudotyped viruses were derived from ancestral Wuhan-Hu-1 with the following amino acid substitutions: (prototype [D614G]; omicron subvariants BA.4 and BA.5, designated BA.4/BA.5 for identical spike sequences between BA.4 and BA.5 [T19I, L24S, ΔP25, ΔP26, ΔA27, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681G, N764K, D796Y, Q954H, N969K]); omicron subvariant BQ.1.1 [T19I, L24S, ΔP25, ΔP26, ΔA27, H69-, V70-, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K]; omicron subvariant XBB.1.5 [T19I, L24S, ΔP25, ΔP26, ΔA27, V83A, G142D, Y145Q, ΔH146, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K]; omicron subvariant XBB.1.16 [T19I, L24S, ΔP25, ΔP26, ΔA27, V83A, G142D, Y145Q, ΔH146, E180V, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478R, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K].

VSV-based SARS-CoV-2 Pseudovirus Neutralization Assay

Codon-optimized full-length spike genes (Wuhan-1 with D614G, BA.4/BA.5, XBB.1.5, XBB.1.16, XBB.2.3.2, EG.5.1, FL.1.5.1, BA.2.86) were cloned into a pCAGGS vector. Spike

genes contained the following mutations: (a) BA.4/BA.5: T19I, L24- P25- P26-, A27S H69-V70-, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K; (b) XBB.1.5: T19I, L24-, P25-, P26-, A27S, V83A, G142D, Y144-, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K; (c) XBB.1.16: T19I, L24-, P25-, P26-, A27S, V83A, G142D, Y144-, H146Q, E180V, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478R, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K; (d) XBB.2.3.2: T19I, L24-, P25-, P26-, A27S, V83A, G142D, Y144-, H146Q, Q183E, G184V, V213E, D253G, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, P521S, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K; (e) EG.5.1: T19I L24- P25- P26- A27S Q52H V83A G142D Y144- H146Q Q183E V213E G252V G339H R346T L368I S371F S373P S375F T376A D405N R408S K417N N440K V445P G446S F456L N460K S477N T478K E484A F486P F490S Q498R N501Y Y505H D614G H655Y N679K P681H N764K D796Y Q954H N969K; (f) FL.1.5.1: T19I L24- P25- P26- A27S V83A G142D Y144- H1460 O183E V213E G252V G339H R346T L368I S371F S373P S375F T376A D405N R408S K417N N440K V445P G446S F456L N460K S477N T478R E484A F486P F490S Q498R N501Y Y505H D614G H655Y N679K P681H A701V N764K D796Y Q954H N969K; BA.2.86: ins16MPLF T19I R21T L24- P25- P26- A27S S50L H69- V70- V127F G142D Y144-F157S R158G N211- L212I V213G L216F H245N A264D I332V G339H K356T S371F S373P S375F T376A R403K D405N R408S K417N N440K V445H G446S N450D L452W N460K S477N T478K N481K V483- E484K F486P Q498R N501Y Y505H E554K A570V D614G P621S H655Y N679K P681R N764K D796Y S939F O954H N969K P1143L. To generate VSV∆G-based SARS-CoV-2 pseudovirus, BHK-21/WI-2 cells were transfected with the spike expression plasmid and infected by VSVAG-firefly-luciferase as previously described (Whitt 2010 Journal of Virological Methods; PMID 20709108). Vero E6 cells (ATCC, CRL-1586) were used as target cells for the neutralization assay and maintained in DMEM supplemented with 10% fetal bovine serum. To perform neutralization assay, serum samples were heat-inactivated for 45 min at 56°C, and serial dilutions were made in DMEM supplemented with 10% FBS. The diluted serum samples or culture medium (serving as virus only control) were mixed with VSVAG-based SARS-CoV-2 pseudovirus and incubated at 37°C for 45 min. The inoculum virus or virus-serum mix was subsequently used to infect Vero E6 cells for 18 h at 37°C. At 18 h post infection, an equal volume of One-Glo reagent (Promega: E6120) was added to culture medium for readout using BMG PHERAstar FSX plate reader. The percentage of neutralization was calculated based on relative light units of the virus control, and subsequently analyzed using four parameter logistic curve (GraphPad Prism 8.0).






Figure S1. Distribution of neutralizing antibody titers (ID50 log₁₀) in Figure 1 detected in the pseudovirus assay against omicron XBB.1.5, XBB.1.16, BA.4/BA.5, BQ.1.1 and ancestral SARS-CoV-2 (D614G) is shown for serum samples collected before the booster dose of 50- μ g of monovalent mRNA-1273.815 or 50- μ g of bivalent mRNA-1273.231, and at 15 days after the booster dose (Day 15) in the per-protocol set for immunogenicity (with and without prior SARS-CoV-2 infection). The circles are values from individual serum samples. Pseudovirus neutralizing antibody assay lower limits of quantification (LLOQ) are 18.5 (1.3 log₁₀) for ancestral SARS-CoV-2 (D614G) and 36.7 (1.6 log₁₀) for omicron BA.4/BA.5; upper limits of quantification (ULOQ) are 45,118 (4.7 log₁₀) for ancestral SARS-CoV-2 (D614G) and 13,705 (4.1 log₁₀) for omicron BA.4/BA.5. The Limits of Detection are 10 for XBB.1.5, XBB.1.16 and BQ.1.1. Boxes and horizontal bars denote interquartile ranges (IQR) and median endpoint titers; whisker endpoints are the maximum and minimum values below or above the median ±1.5 times the IQR.

Table S1. Neutralizing Antibodies Titers and Geometric-fold Rises After 3rd Booster Dose of XBB.1.5-Containing Monovalent and Bivalent Vaccines Against XBB.1.5, XBB.1.16, BA.4/BA.5 and BQ.1.1 Variants and Ancestral SARS-CoV-2 (D614G), Per-protocol Immunogenicity Set

	Monovalent mRNA-1273.815 (XBB.1.5) 50 μg	Bivalent mRNA-1273.231 (XBB.1.5 + BA.4/5) 50 μg
	N=49	N=50
XBB.1.5		
Pre-booster, n	49	50
GM Level (95% CI)	154.7 (106.8-224.1)	158.8 (109.9-229.3)
Day 15, n	49	50
GMT (95% CI)	2579.0 (1809.1-3676.7)	1838.1 (1265.9-2668.9)
GMFR (95% CI)	16.7 (12.8-21.7)	11.6 (8.7-15.4)
XBB.1.16		
Pre-booster, n	47	50
GM Level (95% CI)	221.0 (153.9-317.3)	193.9 (134.1-280.3)
Day 15, n	47	50
GM Level (95% CI)	2262.6 (1570.1-3260.6)	1799.9 (1297.2-2497.5)
GMFR (95% CI)	11.4 (8.5-15.4)	9.3 (7.0-12.3)
BA.4/BA.5		
Pre-booster, n	49	50
GM Level (95% CI)	1540.7 (1127.2-2105.8)	1878.1 (1350.9-2611.1)
Day 15, n	49	50
GM Level (95% CI)	9673.4 (6965.6-13433.8)	9904.8 (7610.8-12890.1)
GMFR (95% CI)	6.3 (4.8, 8.2)	5.3 (3.9-7.1)
BQ.1.1		· · · ·
Pre-booster, n	48	50
GM Level (95% CI)	347.5 (249.5-483.9)	312.8 (221.4-441.9)
Day 15, n	48	50
GM Level (95% CI)	1894.1 (1383.2, 2593.6)	1895.4 (1348.2-2664.7)
GMFR (95% CI)	5.8 (4.7-7.3)	6.1 (4.6-7.9)
Ancestral SARS-CoV-2 (D614G)	
Pre-booster, n	49	50
GM Level (95% CI)	2780.3 (2146.5-3601.3)	2421.3 (1788.4-3278.1)
Day 15, n	49	49
GM Level (95% CI)	7749.7 (5943.7-10104.3)	5860.9 (4558.0-7536.3)
GMFR (95% CI)	2.8 (2.2-3.5)	2.3 (1.9-2.8)
n = number of observations at corres = geometric mean fold rise. 95% CI is log-transformed values for GM value GMFR is GM Level at Day 15 relative	coording timepoint; GMT = geometric mean titer; 95 calculated based on the t-distribution of the log-tra and GM fold-rise, respectively, then back transform to GM Level at pre-booster. Antibody values repoint $A = 10^{-10} + 10^{-10}$	i% CI = 95% confidence interval; GMF ansformed values or the difference in t ned to the original scale for presentatio rted as below the lower limit of

GMFR is GM Level at Day 15 relative to GM Level at pre-booster. Antibody values reported as below the lower limit of quantification (LLOQ: 36.7 for BA.4/BA.5; 18.5 for ancestral SARS-CoV-2 (D614G)) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ: 13,705 for BA.4/BA.5; 45,188 for Ancestral SARS-CoV-2 (D614G)) are replaced by the ULOQ if actual values are not available. Antibody values reported as below the lower limit of detection (LOD: 10 for XBB.1.5; 10 for XBB.1.16; 10 for BQ.1.1) are replaced by 0.5 x LOD.

Table S2. Neutralizing Antibodies Titers and Geometric-fold Rises After 3rd Booster Dose of XBB.1.5-Containing Monovalent and Bivalent Vaccines Against XBB.1.5, XBB.1.16, BA.4/BA.5 and BQ.1.1 Variants and Ancestral SARS-CoV-2 (D614G) by Pre-booster SARS-CoV-2 Status

	No Prior Infection		Prior Infection		
-	Monovalent mRNA-1273.815 (XBB.1.5) 50 μg N=16	Bivalent mRNA-1273.231 (XBB.1.5 + BA.4/5) 50 μg N=11	Monovalent mRNA-1273.815 (XBB.1.5) 50 μg N=33	Bivalent mRNA-1273.231 (XBB.1.5 + BA.4/5) 50 μg N=39	
XBB.1.5	N-10	N-11	11-00	N-00	
Pre-booster, n	16	11	33	39	
GM Level (95% CI)	81.7 (40.7-164.1)	65.2 (33.8-125.6)	210.8 (138.8-320.3)	204.1 (135.3-307.9)	
Day 15, n	16	11	33	39	
GMT (95% CI)	1639.3 (742.9-3617.4)	1256.9 (537.5-2939.4)	3212.8 (2215.2-4659.5)	2046.1 (1333.2-3140.1)	
GMFR (95% CI)	20.1 (12.5-32.1)	19.3 (8.5-43.8)	15.2 (10.9-21.2)	10.0 (7.5-13.5)	
XBB.1.16					
Pre-booster, n	14	11	33	39	
GM Level (95% CI)	133.7 (67.9-263.2)	71.6 (33.9-150.8)	273.5 (178.0-420.1)	256.9 (173.3-380.7)	
Day 15, n	16	11	33	39	
GM Level (95% CI)	1409.5 (646.1-3074.8)	1452.8 (618.3-3413.6)	2846.2 (1912.7-4235.4)	1912.0 (1326.8-2755.2)	
GMFR (95% CI)	14.2 (8.5-24.0)	20.3 (9.6-43.0)	10.4 (7.2-15.1)	7.4 (5.6-9.8)	
BA.4/BA.5					
Pre-booster, n	16	11	33	39	
GM Level (95% CI)	691.3 (438.9-1088.7)	844.4 (405.9-1756.9)	2272.3 (1606.0-3215.0)	2353.1 (1653.9-3347.9)	
Day 15, n	16	11	33	39	
GM Level (95% CI)	6254.4 (3482.3-11233.1)	9269.3 (6282.1-13676.8)	11951.0 (8035.2-17775.2)	10091.8 (7276.3-13996.6)	
GMFR (95% CI)	9.0 (5.9-13.9)	11.0 (4.5-27.0)	5.3 (3.7-7.4)	4.3 (3.3-5.6)	
BQ.1.1					
Pre-booster, n	15	11	33	39	
GM Level (95% CI)	247.7 (125.7-488.2)	142.2 (71.7-281.9)	405.3 (275.9-595.3)	390.7 (266.1-573.5)	
Day 15, n	16	11	33	39	
GM Level (95% CI)	1438.3 (125.7-488.2)	1376.1 (877.5-2157.8)	2164.5 (1554.6-3013.6)	2074.6 (1360.0-3164.5)	
GMFR (95% CI)	7.1 (4.6-11.1)	9.7 (4.5-20.9)	5.3 (4.1-7.0)	5.3 (4.0-7.0)	
Ancestral SARS-CoV-2	(D614G)				
Pre-booster, n	16	11	33	39	
GM Level (95% CI)	2179.9 (1205.3-3942.6)	1772.2 (820.7-3827.2)	3128.4 (2380.6-4111.1)	2644.0 (1886.7-3705.3)	
Day 15, n	16	10	33	39	
	7743.5 (4611.2-13003.4)	6226.5 (3849.4-10071.4)	7752.7 (5605.8-10721.9)	5770.7 (4272.7-7793.9)	
GM Level (95% CI)					

geometric mean fold rise. 95% CI is calculated based on the t-distribution of the log-transformed values or the difference in the logtransformed values for GM value and GM fold-rise, respectively, then back transformed to the original scale for presentation. GMFR is GM Level at Day 15 relative to GM Level at pre-booster. Antibody values reported as below the lower limit of quantification (LLOQ: 36.7 for BA.4/BA.5; 18.5 for ancestral SARS-CoV-2 [D614G]) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ: 13,705 for BA.4/BA.5; 45,188 for Ancestral SARS-CoV-2 [D614G]) are replaced by the ULOQ if actual values are not available. Antibody values reported as below the lower limit of detection (LOD: 10 for XBB.1.5; 10 for XBB.1.16; 10 for BQ.1.1) are replaced by 0.5 x LOD.

Solicited Adverse Reaction	Monovalent mRNA-1273.815 (XBB.1.5) 50 μg (N=50)	Bivalent mRNA-1273.231 (XBB.1.5 + BA.4/5) 50 µg (N=51)
Solicited Adverse Reactions - N1	50	51
Any Solicited	38 (76.0)	45 (88.2)
Grade 1	23 (46.0)	28 (54.9)
Grade 2	14 (28.0)	11 (21.6)
Grade 3	1 (2.0)	6 (11.8)
Solicited Local Adverse Reactions - N1	50	51
Any Local	34 (68.0)	43 (84.3)
Grade 1	26 (52.0)	33 (64.7)
Grade 2	8 (16.0)	7 (13.7)
Grade 3	0	3 (5.9)
Pain - N1	50	51
Any	34 (68.0)	42 (82.4)
Grade 1	28 (56.0)	33 (64.7)
Grade 2	6 (12.0)	7 (13.7)
Grade 3	0	2 (3.9)
Erythema (Redness) - N1	50	51
Any	2 (4.0)	1 (2.0)
Grade 1		0
Grade 2	1 (2.0)	0
	1 (2.0)	
Grade 3	0	1 (2.0)
Swelling (Hardness) - N1	50	51
Any	5 (10.0)	6 (11.8)
Grade 1	2 (4.0)	3 (5.9)
Grade 2	3 (6.0)	2 (3.9)
Grade 3	0	1 (2.0)
Axillary Swelling or Tenderness - N1	50	51
Any	8 (16.0)	14 (27.5)
Grade 1	8 (16.0)	12 (23.5)
Grade 2	0	2 (3.9)
Grade 3	0	0
Solicited Systemic Adverse Reactions - N1	50	51
Any Systemic	29 (58.0)	33 (64.7)
Grade 1	16 (32.0)	17 (33.3)
Grade 2	12 (24.0)	12 (23.5)
Grade 3	1 (2.0)	4 (7.8)
Fever - N1	50	51
Any	3 (6.0)	1 (2.0)
Grade 1	1 (2.0)	1 (2.0)
Grade 2	1 (2.0)	0
Grade 3	1 (2.0)	0
Headache - N1	50	51
Any	17 (34.0)	23 (45.1)
Grade 1	14 (28.0)	17 (33.3)
Grade 2	3 (6.0)	5 (9.8)
Grade 3	0	1 (2.0)
Fatigue - N1	50	51
Any	22 (44.0)	25 (49.0)
Grade 1	12 (24.0)	14 (27.5)
Grade 2	10 (20.0)	9 (17.6)
Grade 3	0	2 (3.9)
Myalgia - N1	50	51
Any	19 (38.0)	19 (37.3)
Grade 1	14 (28.0)	11 (21.6)

 Table S3. Solicited Local and Systemic Adverse Reactions (Solicited Safety Set)

Grade 2	5 (10.0)	6 (11.8)
Grade 3	0	2 (3.9)
Arthralgia - N1	50	51
Any	14 (28.0)	15 (29.4)
Grade 1	12 (24.0)	8 (15.7)
Grade 2	2 (4.0)	6 (11.8)
Grade 3	0	1 (2.0)
Nausea/Vomiting - N1	50	51
Any	4 (8.0)	5 (9.8)
Grade 1	4 (8.0)	3 (5.9)
Grade 2	0	2 (3.9)
Grade 3	0	0
Chills - N1	50	51
Any	7 (14.0)	12 (23.5)
Grade 1	5 (10.0)	9 (17.6)
Grade 2	2 (4.0)	3 (5.9)
Grade 3	0	0
N1=Number of exposed participants with data for t number of exposed participants who submitted any defined as: G1 = $25 - 50$ mm; G2 = $51 - 100$ mm 38.4 C; G2 = $38.5 - 38.9$ C; G3 = $39 - 40$ C; G4	y data for the event (N1). Toxicity grant, G3 = > 100 mm. Toxicity grade fo	ade for Erythema (Redness) is

n (%)	Monovalent mRNA-1273.815 (XBB.1.5) 50 μg (N=50)	Bivalent mRNA-1273.231 (XBB.1.5 + BA.4/BA.5) 50 µg (N=51)
Unsolicited AEs Regardless of Relationship to Study Vaccination		
All	5 (10.0)	7 (13.7)
Serious	0	0
Fatal	0	0
Medically-Attended	4 (8.0)	4 (7.8)
Unsolicited AEs Related to Study Vaccination		
All	1 (2.0)	2 (3.9)
Serious	0	0
Fatal	0	0
Medically-Attended	1 (2.0)	0

Table S4. Unsolicited Treatment-emergent Adverse Reactions (Safety Set)

study vaccination or any event already present that worsened in intensity or frequency after vaccination. Percentages are based on the number of participants in the safety set.

Supplement References

1. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43-50.